Sugi Predict

Sugi Predict / Compounds / SCHEMBL707397

SCHEMBL707397

SCHEMBL707397

CCN(CC)CCCC(Nc1ccnc2cc(Cl)ccc12)C(=O)O

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KCNH2 Q12809 4/20 0.72
▸ NR4A2 P43354 4/20 0.72
▸ CHRM2 P08172 3/20 0.72
▸ CHRM1 P11229 3/20 0.72
▸ ADRA2C P18825 3/20 0.72
▸ CYP2D6 P10635 3/20 0.72
▸ CHRM4 P08173 2/20 0.72
▸ CHRM5 P08912 2/20 0.72
▸ ADRA2A P08913 2/20 0.72
▸ ADRA2B P18089 2/20 0.72
▸ CHRM3 P20309 2/20 0.72
▸ TMEM97 Q5BJF2 2/20 0.72
▸ SIGMAR1 Q99720 2/20 0.72
▸ ACE2 Q9BYF1 2/20 0.72
▸ APP P05067 2/20 0.72
▸ CYP2C19 P33261 2/20 0.72
▸ TDP1 Q9NUW8 1/20 0.72
▸ PRNP P04156 1/20 0.72
▸ NQO2 P16083 1/20 0.72
▸ MTOR P42345 1/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL710004 0.94 CHRM2 (0.76) KCNH2NR4A2CHRM2CHRM1ADRA2C
SCHEMBL4742308 0.89 CHRM2 (0.56) KCNH2NR4A2CHRM2CHRM1ADRA2C
SCHEMBL708741 0.89 CHRM2 (0.56) KCNH2NR4A2CHRM2CHRM1ADRA2C
Chloroquine SCHEMBL28895653 0.88 CHRM2 (0.90) KCNH2NR4A2CHRM2CHRM1ADRA2C
Chloroquine SCHEMBL28469482 0.87 CHRM2 (0.85) KCNH2NR4A2CHRM2CHRM1ADRA2C
Chloroquine SCHEMBL4745454 0.85 CHRM2 (0.85) KCNH2NR4A2CHRM2CHRM1ADRA2C
SCHEMBL1695371 0.85 CACNA2D1 (0.51) KCNH2NR4A2CHRM2CHRM1ADRA2C
SCHEMBL1147595 0.85 NR4A2 (0.81) KCNH2NR4A2CHRM2CHRM1ADRA2C
Chloroquine SCHEMBL27814047 0.84 CHRM2 (0.96) KCNH2NR4A2CHRM2CHRM1ADRA2C
Chloroquine SCHEMBL8934 0.84 CHRM2 (1.00) KCNH2NR4A2CHRM2CHRM1ADRA2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 205 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230416786-A1 USE OF AMINOQUINOLINE COMPOUNDS FOR HIGHER GENE INTEGRATION CELLECTIS SA (FR) 2023-12-28 — — US claimed
EP-4251746-A1 USE OF AMINOQUINOLINE COMPOUNDS FOR HIGHER GENE INTEGRATION Cellectis SA (FR) 2023-10-04 — — EP claimed
US-20230000893-A1 Antiviral Agents and Nucleoside Analogs for Treatment of Zika Virus UNIV EMORY (US) 2023-01-05 — — US claimed
WO-2022112596-A1 USE OF AMINOQUINOLINE COMPOUNDS FOR HIGHER GENE INTEGRATION CELLECTIS SA (FR) 2022-06-02 — — WO claimed
EP-1581167-A4 COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE AND TARDIVE DYSKINESIAS ALPHA RES GROUP LLC (US) 2008-10-29 — — EP claimed
JP-2006514917-A — — 2006-05-18 — — JP claimed
EP-1581167-A2 COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE AND TARDIVE DYSKINESIAS Alpha Research Group, LLC (US) 2005-10-05 — — EP claimed
EP-1261340-A4 COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE ALPHA RES GROUP LLC (US) 2005-05-04 — — EP claimed
US-20040229908-A1 Compositions and methods for the treatment of Parkinson's disease and tardive dyskinesias Greenlee, Winner and Sullivan, P.C. 2004-11-18 — — US claimed
WO-2004004660-A2 COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON’S DISEASE AND TARDIVE DYSKINESIAS ALPHA RESEARCH GROUP, L.L.C. (US) 2004-01-15 — — WO claimed
JP-2004500331-A — — 2004-01-08 — — JP claimed
US-20020198231-A1 Compositions and methods for the treatment of Parkinson's disease Greenlee, Winner and Sullivan, P.C. 2002-12-26 — — US claimed
EP-1261340-A2 COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE Alpha Research Group, LLC (US) 2002-12-04 — — EP claimed
WO-2001003649-A2 COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE ALPHA RESEARCH GROUP, LLC (US) 2001-01-18 — — WO claimed
WO-2026102333-A1 METHODS OF TREATING CARDIOMYOPATHY USING PRKAG2-TARGETING ANTIBODY-OLIGONUCLEOTIDE CONJUGATES Atrium Therapeutics, Inc. (US) 2026-05-15 — — WO disclosed
EP-4735051-A1 COMPOSITIONS AND METHODS OF USING PLN-TARGETING ANTIBODY-OLIGONUCLEOTIDE CONJUGATES Atrium Therapeutics, Inc. (US) 2026-05-06 — — EP disclosed
EP-4735602-A2 COMPOSITIONS AND METHODS OF USING PRKAG2-TARGETING ANTIBODY-OLIGONUCLEOTIDE CONJUGATES ABSTRACT Atrium Therapeutics, Inc. (US) 2026-05-06 — — EP disclosed
EP-1261340-A2 COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE Alpha Research Group, LLC (US) 2002-12-04 — — EP disclosed
US-6417177-B1 Chloroquine derivatives for the treatment of Parkinson's disease ALPHA RESEARCH GROUP, LLC 2002-07-09 — — US disclosed
WO-2001003649-A2 COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE ALPHA RESEARCH GROUP, LLC (US) 2001-01-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230000893-A1 Antiviral Agents and Nucleoside Analogs for Treatment of Zika Virus SAMHD1, PNP, NUDT1 KCNH2 3605/4885NR4A2 827/4885CHRM2 3532/4885
US-20230416786-A1 USE OF AMINOQUINOLINE COMPOUNDS FOR HIGHER GENE INTEGRATION ERCC4, LIG4, LIG3 KCNH2 4314/4885NR4A2 2104/4885CHRM2 4834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.